Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BR9001 vs BR900A in Healthy Subjects
NCT03718611Phase 1Completed
- Sponsor
- Boryung
- Start
- Oct 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tofacitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Boryung. Primary endpoints: Maximum concentration of drug in plasma and Area under the plasma drug concentration-time curve to the last observed concentration. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03718611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03718611.